Collaborative Clinical Cancer Trials Conference

between the US and Japan in Karuizawa

Recent Results and Future Directions of Common Arm Trials

-Final Program-

Date: September 7-8, 2007

Location: Kajima no Mori Hall, Hotel Kajima no Mori, Nagano, Japan

September 7(Fri), 2007

12:30

Opening remarks

Dr. Hiromi Wada

Chairman

Japan-Multinational Trial Organization (JMTO)

Session I

Gastric Cancer

12:40-14:00

Chairpersons:

Dr. Seiji Satoh

Dr. Yung-Jue Bang

12:40

1) Combination therapy with S-1 and other cytotoxic drugs overcomes tumor cell resistance to fluoropyrimidines in vivo

Dr. Masakazu Fukushima

 ${\sf Tokushima\ Research\ Center,\ Taiho\ Pharmaceutical\ Co.,\ Ltd.}$

Dr. Hiromi Wada

Kyoto University

13:00

 A Phase II common arm trial of neoadjuvant chemotherapy for resectable advanced gastric cancer using S-1/CDDP

Dr. Seiji Satoh

Akita University Hospital

```
13:20
```

3) S-1 in gastric cancer chemotherapy

Dr. Hyun C. Chung

Yonsei University College of Medicine

13:40

4) International collaboration for gastric cancer trials

Dr. Yung-Jue Bang

Seoul National University Hospital

Session II

Endoscopic Study for Lung Cancer

14:00-14:40

Chairpersons:

Dr. Thomas G. Sutedja

Dr. Seiki Hasegawa

14:00

 Evaluation of mediastinal nodal metastasis with endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) in operable lung cancer patients

Dr. Fumihiro Tanaka

Hyogo College of Medicine

14:20

2) Minimal invasive T and N working concepts

Dr. Thomas G. Sutedja

VU University Academic Medical Center

Session III

Clinical Trials

14:40-15:40

Chairpersons:

Dr. John J. Crowley

Dr. Satoshi Teramukai

14:40

1) Issues in the analysis of molecular epidemiologic data

Dr. Mary W. Redman

Fred Hutchinson Cancer Research Center

15:00

2) Clinical trial designs for targeted agents

Dr. John J. Crowley

Cancer Research And Biostatistics (CRAB)

15:20

3) Perspective on Lung Cancer Management in Japan

Dr. Ryosuke Tsuchiya

National Cancer Center Hospital

15:40-15:50 -Coffee Break-

Session IV

Non-Small Cell Lung Cancer - I and Small Cell Lung Cancer

15:50-17:50

Chairpersons:

Dr. Tetsuya Mitsudomi

Dr. Fumihiro Tanaka

15:50

1) Mutations of the EGFR or related genes and targeted therapy of lung cancer

Dr. Tetsuya Mitsudomi

Aichi Cancer Center Hospital

16:10

2) Prevalence of EGFR gene mutations on surgical specimens.

Experience in Kyoto University Hospital

Dr. Makoto Sonobe

Kyoto University Hospital

16:30

 A phase II trial of pre-operative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small cell lung cancers: report of a Japan Clinical Oncology Group trial (JCOG 9806)

Dr. Masahiro Tsuboi

Tokyo Medical University & Hospital

16:50

4) Surgical treatment of Pancoast tumor —Surgical approach with combination of open thoracotomy and VATS—

Dr. Seiki Hasegawa

Hyogo College of Medicine

17:10

5) International randomized study to compare Cyberknife Stereotact Radiosurgery with surgical resection in stage I non-small cell lung cancer

(Lung Cancer STARS Trial)

Dr. Jack A. Roth

The University of Texas MD Anderson Cancer Center

17:30

6) Current status and future directions of treatment for relapsed small-cell lung cancer (SCLC)

Dr. Koichi Goto

National Cancer Center Hospital East

```
Session V
```

Key Note Address

17:50-18:10

Chairperson:

Dr. Hiromi Wada

17:50

Possibility for joint US-Japan global trials

Dr. Nagahiro Saijo

National Cancer Center Hospital East

19:00-21:00 -Banquet-

September 8(Sat), 2007

Session VI

8:00-10:00

Chairpersons:

Dr. David R. Gandara

Dr. Masaaki Kawahara

1) Common Arm Trials (CATs) in Japan and the US

8:00

1A) Rationale for Common Arm Studies

Dr. David R. Gandara

University of California Davis Cancer Center

8:10

1B) The four-arm cooperative study (FACS) for advanced non-small cell

Dr. Kaoru Kubota

lung cancer

National Cancer Center Hospital East

1C) JMTO LC00-03 Trial including QOL

Dr. Masaaki Kawahara

Nat' I Hospital Org. Kinki-chuo Chest Medical Center

8:50

 Pharmacogenomic analysis of Japan-SWOG common arm study in advanced stage Non-Small Cell Lung Cancer (NSCLC)

Dr. Philip C. Mack

University of California Davis Cancer Center

9:10

3) Common arm trials in the US and Japan

Dr. David R. Gandara

University of California Davis Cancer Center

9:20

4) International trials for non-small cell lung cancer in Japan

Dr. Masahiro Fukuoka

Sakai Hospital, Kinki University School of Medicine

9:40

5) Newer clinical trial infrastructure and paradigm in Japan—The role of the Translational Research Informatics Center

Dr. Masanori Fukushima

Translational Research Center, Kyoto University &

Translational Research Informatics Center, Kobe

10:00-10:10 -Coffee Break-

Session VII

Non-small Cell Lung Cancer - III

10:10-10:50

Chairpersons:

Dr. Yukito Ichinose

Dr. Kaoru Kubota

10:10

 Phase II study of docetaxel and S-1 combination therapy in patients with previously treated non-small-cell lung cancer

Dr. Shinji Atagi

Nat' I Hospital Org. Kinki-chuo Chest Medical Center

10:30

 Recent results and new trends of neoadjuvant and adjuvant chemotherapy for early stage NSCLC in Japan

Dr. Yukito Ichinose

National Kyushu Cancer Center

Session VIII

Small Cell Lung Cancer -LD -

10:50-11:30

Chairpersons:

Dr. Primo N. Lara, Jr.

Dr. Yasushi Nagata

10:50

 A Phase II study of accelerated high dose thoracic irradiation with concurrent chemoradiotherapy for patients with LD SCLC as a common arm trial of the US trial

Dr. Yasushi Nagata

Graduate School of Medicine, Kyoto University

```
11:10
```

 Recent JCOG trials of combined modality treatment for limited small-cell lung cancer

Dr. Kaoru Kubota

National Cancer Center Hospital East

11:30-12:30 -Lunch-

Session IX

Small Cell Lung Cancer -ED-

12:30-13:10

Chairpersons:

Dr. Primo N. Lara, Jr.

Dr. Tadashi Mio

12:30

1) Recent trials of chemotherapy for extensive small cell lung cancer in

the JMTO

Dr. Tadashi Mio

Graduate School of Medicine, Kyoto University

12:50

 Cisplatin (Cis)/etoposide (VP16) vs. cis/irinotecan (CPT11) in extensive stage small cell lung cancer (E-SCLC): pharmacogenomic

(PG) and comparative toxicity analysis of JCOG 9511 and SWOG $\,$ 0124 $\,$

Dr. Primo N. Lara, Jr.

University of California Davis Cancer Center

Session X

Prognostic Index of Ovarian Cancer and Ethnicity, Gender or Other Factors for the Innovating Therapy of Lung Cancer

13:10-14:20

Chairpersons:

Dr. Philip C. Mack

Dr. Tadashi Mio

13:10

1) PIEPOC: A New Prognostic Index for Advanced Epithelial Ovarian

Cancer-JMTO OC01-01

Dr. Satoshi Teramukai

Kyoto University Hospital

13:30

 $\begin{tabular}{ll} \bf 2) & \bf Significant influence of smoking status and gender on the clinical \\ \bf 1) & \bf 1) & \bf 2) & \bf 3) &$

outcome in the patients with non-small cell lung cancer:

A comprehensive analysis of the 25554 Japanese patients

Dr. Tomoya Kawaguchi

Nat' I Hospital Org. Kinki-chuo Chest Medical Center

13:50

3) S0424: Molecular Epidemiology in Women and Men, Smokers and

Never Smokers with NSCLC

Dr. David R. Gandara

Southwest Oncology Group(SWOG)

14:10

Closing Remarks

Dr. Masaaki Kawahara

Executive Director

Japan-Multinational Trial Organization (JMTO)